Celgene-CELG Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG

CELG 108.24

0.0%

Nov 22 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (540)	6/21/2001 8:01:16 PM
From: Miljenko Zuanic	Read Replies (2) of 804

<<It is clear to me that thal will get approval for MM. At that point sales will certainly get a boost, as CELG will be able to properly promote the drug.>> For what indication: fist line therapy, or only refractory? <<As of February 2001, 45 patients had been enrolled in the study, and 3 (7 percent) had had thrombotic events. Two patients had documented deep venous thrombosis; acute dyspnea developed in the third patient, who died within an hour in a hospital emergency room, with a clinical diagnosis of pulmonary embolism.>> This was very serious DVT when one pts died. They still do not know what is mechanism? Drug-drug interaction? Addition of the trombolitic drug to regime in long term cancer therapy does not sound good to me. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next